Merck, Caprotec Collaborate on Protein-Drug Interaction Research
 
Caprotec Bioanalytics said this week it and Merck KGaA reached an agreement for use of Caprotec’s Capture Compound Mass Spectrometry technology for the identification of relevant protein-drug molecule interactions. Merck KGaA was acting on behalf of its Merck Serono division in reaching the agreement with Caprotec.
 
The technology will be applied to an undisclosed Merck Serono research project.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.